https://www.pharmaradar360.com/article/6b17b0dc93b98773Pharma Surgeen2026-05-14T11:32:28.000ZBiogen's anti-tau Alzheimer's drug misses Phase 2 goal, but will move to pivotal studyhttps://www.pharmaradar360.com/article/a59159619c2a23bfPharma Surgeen2026-05-14T11:30:00.000ZKFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitorhttps://www.pharmaradar360.com/article/e9110d9f8d781527Pharma Surgeen2026-05-14T11:16:56.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Marzo de 2026https://www.pharmaradar360.com/article/511bf182aa23b468Pharma Surgeen2026-05-14T11:00:17.000ZRegenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalhttps://www.pharmaradar360.com/article/bd8941ecef5ab71cPharma Surgeen2026-05-14T11:00:00.000ZTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumabhttps://www.pharmaradar360.com/article/6fa75b549a23ca12Pharma Surgeen2026-05-14T11:00:00.000ZCanada nabs time on Extremely Large Telescope with groundbreaking instrument investmenthttps://www.pharmaradar360.com/article/8c37ca7058d15441Pharma Surgeen2026-05-14T11:00:00.000ZLilly and UNICEF collaborate to give millions of children a healthier starthttps://www.pharmaradar360.com/article/87fd130533d9037fPharma Surgeen2026-05-14T10:35:10.000ZZydus to acquire Assertio in $166m dealhttps://www.pharmaradar360.com/article/bbb689d5fe14b5c1Pharma Surgeen2026-05-14T10:31:51.000ZBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclextahttps://www.pharmaradar360.com/article/c3de1aa3e383a5e0Pharma Surgeen2026-05-14T10:30:00.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/dccf20beaf9ecd41Pharma Surgeen2026-05-14T10:30:00.000ZHenry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growthhttps://www.pharmaradar360.com/article/f2fea7eda8823b5bPharma Surgeen2026-05-14T10:12:14.000ZUniversities key to SA’s energy transition, Ramokgopa tells SUhttps://www.pharmaradar360.com/article/d8051d51856f357cPharma Surgeen2026-05-14T10:11:11.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΑΠΡΙΛΙΟΥ 2026https://www.pharmaradar360.com/article/c77d214d5ba1ec09Pharma Surgeen2026-05-14T10:05:07.000ZReunión del Comité de Medicamentos de Uso Humano de mayo de 2026https://www.pharmaradar360.com/article/7a15d857b7257fb6Pharma Surgeen2026-05-14T10:00:00.000ZHow Misinformation Impacts Evidence-Based Sciencehttps://www.pharmaradar360.com/article/f082fd4cfe2ce586Pharma Surgeen2026-05-14T10:00:00.000Z25 Years of Lessons Learned: Q&A with Ketan Mehtahttps://www.pharmaradar360.com/article/fb59c13edfb690f0Pharma Surgeen2026-05-14T09:59:22.000ZOntozry (cenobamate): Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/09e2bd1a6249ac8bPharma Surgeen2026-05-14T09:59:11.000ZClass 4 Medicines Defect Notification: Fresenius Medical Care Deutschland GmbH, balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, EL(26)A/24https://www.pharmaradar360.com/article/1d078c455d2ef0c3Pharma Surgeen2026-05-14T09:39:15.000ZQuartzBio secures Eir Partners investment for trial intelligence platformhttps://www.pharmaradar360.com/article/3a026fa9dd18b4eaPharma Surgeen2026-05-14T09:00:42.000ZUK’s largest independent gambling harms research centre launcheshttps://www.pharmaradar360.com/article/921e5f64e6e9fec4Pharma Surgeen2026-05-14T09:00:00.000ZPrior heart attack linked to faster declines in thinking and memory skillshttps://www.pharmaradar360.com/article/c7996c78b7210a6ePharma Surgeen2026-05-14T08:56:07.000ZOsel and partners launch Phase IIb FLIP-2 trial of Lactin-Vhttps://www.pharmaradar360.com/article/763821b29100e1eaPharma Surgeen2026-05-14T08:51:22.000ZPfizer receives EC approval for Hympavzi to treat haemophiliahttps://www.pharmaradar360.com/article/88811b599f2ea699Pharma Surgeen2026-05-14T08:32:46.000ZVisiting St Thomas' Hospital on Saturday 16 Mayhttps://www.pharmaradar360.com/article/84d6977cac80940bPharma Surgeen2026-05-14T08:30:00.000ZThe Clínic promotes sustainable dialysis with a 22% reduction in CO2 emissionshttps://www.pharmaradar360.com/article/491f82c4ebbad4e9Pharma Surgeen2026-05-14T08:24:39.000ZCountries compete to reform trials in a bid to attract global sponsorshttps://www.pharmaradar360.com/article/aec6b1cf28009a5cPharma Surgeen2026-05-14T08:21:48.000ZObama advisor to speak on AI and democracyhttps://www.pharmaradar360.com/article/90ad1bd91237e8c1Pharma Surgeen2026-05-14T08:21:14.000ZDevelopments in sepsis, antimicrobial resistance, antifungals, and immunotherapieshttps://www.pharmaradar360.com/article/fe31805b7d87a053Pharma Surgeen2026-05-14T08:06:09.000ZDisruptions may occur when sending e-mails to State Agency of Medicines contactshttps://www.pharmaradar360.com/article/e1999d2cf1331e60Pharma Surgeen2026-05-14T08:05:35.000ZTrends in Renal Research: Nephrology’s Shift to Focus and Precisionhttps://www.pharmaradar360.com/article/a823db9d82962a50Pharma Surgeen2026-05-14T08:05:35.000ZTrends in Renal Research: Nephrology’s Shift to Focus and Precisionhttps://www.pharmaradar360.com/article/e56f6f84947acbc2Pharma Surgeen2026-05-14T08:02:51.000ZMaretha Joyce the steady hand behind the sceneshttps://www.pharmaradar360.com/article/e4813e2bc5cea7aePharma Surgeen2026-05-14T08:00:08.000ZThree new Trustees join Board of Quadram Institute Biosciencehttps://www.pharmaradar360.com/article/db3ce5b0d57c27f3Pharma Surgeen2026-05-14T08:00:07.000ZJornada sobre CHESSMEN, la acción conjunta de problemas de suministro de medicamentoshttps://www.pharmaradar360.com/article/b62b0e848a5785f3Pharma Surgeen2026-05-14T08:00:00.000ZLa AEMPS organiza una jornada sobre la acción conjunta CHESSMENhttps://www.pharmaradar360.com/article/e8fa5f3061548bfcPharma Surgeen2026-05-14T07:31:06.000ZNAFDAC becomes the 24th member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Usehttps://www.pharmaradar360.com/article/c52e5dec5706aeb0Pharma Surgeen2026-05-14T07:16:04.000ZRadiologist-AI combo has highest potential to improve pulmonary embolism detection, experts chargehttps://www.pharmaradar360.com/article/e53af21ec29fc000Pharma Surgeen2026-05-14T07:08:21.000ZSolis Mammography opens 4 new imaging centershttps://www.pharmaradar360.com/article/b6f88c1a37470b05Pharma Surgeen2026-05-14T07:01:43.000Z82% of radiologists and other physicians now employed by corporate entitieshttps://www.pharmaradar360.com/article/9b8fc5ff82cba918Pharma Surgeen2026-05-14T07:00:00.000ZDr. Davies highlights med center’s role addressing hantavirus outbreakhttps://www.pharmaradar360.com/article/72606d61808e5295Pharma Surgeen2026-05-14T06:58:00.000ZTwo honored with inaugural Staff Advisory Council awardshttps://www.pharmaradar360.com/article/4a5b6e358f77adccPharma Surgeen2026-05-14T06:57:03.000ZPDBe-SIFTS for protein sequence-structure mappinghttps://www.pharmaradar360.com/article/208fd2834beceaeePharma Surgeen2026-05-14T06:56:00.000ZCeremony today to celebrate UNMC’s expansion in Kearneyhttps://www.pharmaradar360.com/article/564c325e958ccd25Pharma Surgeen2026-05-14T06:54:00.000ZHelp boost UNMC’s community engagement effortshttps://www.pharmaradar360.com/article/e40f6e89b69b98f6Pharma Surgeen2026-05-14T06:52:00.000ZUNMC applications will be unavailable Saturdayhttps://www.pharmaradar360.com/article/a1a8066bf4f0eea5Pharma Surgeen2026-05-14T06:50:00.000ZRegenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapyhttps://www.pharmaradar360.com/article/7f8586137d4d44b5Pharma Surgeen2026-05-14T06:35:00.000ZAptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks developmenthttps://www.pharmaradar360.com/article/324d87f00a14ae15Pharma Surgeen2026-05-14T06:30:58.000ZWest Lancashire trust optimises EPR to improve abdomen pathwayhttps://www.pharmaradar360.com/article/5284e730867fbce1Pharma Surgeen2026-05-14T06:30:00.000Zヒト化抗CD20モノクローナル抗体「ガザイバ」特発性ネフローゼ症候群に対して適応拡大申請https://www.pharmaradar360.com/article/5a938dd78fb47bdcPharma Surgeen2026-05-14T06:30:00.000ZFiling of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndromehttps://www.pharmaradar360.com/article/a7cd0e0fb68a80dfPharma Surgeen2026-05-14T06:29:57.000ZFlinders University breaks new ground in Mount Gambierhttps://www.pharmaradar360.com/article/d9737ffa5ad85571Pharma Surgeen2026-05-14T06:00:00.000ZAstellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/98049e3e1e750d8aPharma Surgeen2026-05-14T05:49:52.000ZAesthetics, built from sciencehttps://www.pharmaradar360.com/article/ccbfe204e1d04e51Pharma Surgeen2026-05-14T05:21:15.000ZProviding a cellular ‘all-clear’ signal to resume protein synthesishttps://www.pharmaradar360.com/article/ab2ca25dee0709a0Pharma Surgeen2026-05-14T05:01:06.000ZFrom Data Chaos to Discovery: Building the Data Foundation for AI-Ready Scientific Researchhttps://www.pharmaradar360.com/article/e28c6bac32336bf6Pharma Surgeen2026-05-14T05:00:37.000ZWho are the Japanese? Huge DNA discovery rewrites historyhttps://www.pharmaradar360.com/article/83f703b7964ba821Pharma Surgeen2026-05-14T04:47:47.000ZDazzling gala commemorates Afrikaans dictionary’s centenary and ties with SUhttps://www.pharmaradar360.com/article/fc26317979f6d21dPharma Surgeen2026-05-14T04:09:08.000Z2025年度 ナース・オブ・ザ・イヤー授賞式を執り行いましたhttps://www.pharmaradar360.com/article/eedca02739dcc910Pharma Surgeen2026-05-14T04:08:13.000Z2026年度 第1回東北大学病院脳卒中・心臓病等総合支援センター県民公開講座in大衡村開催のお知らせ（6/23開催）https://www.pharmaradar360.com/article/1d9683b0d97e22d4Pharma Surgeen2026-05-14T03:34:56.000ZWhat Is Clinical Trials Day? Why Technology Helps Research Risehttps://www.pharmaradar360.com/article/9f5e2588b9b2627fPharma Surgeen2026-05-14T02:06:27.000ZPAI-1阻害薬「TM5614」の抗老化効果をヒトで確認－XPRIZE Healthspanセミファイナル臨床試験結果－https://www.pharmaradar360.com/article/f018438f713582bcPharma Surgeen2026-05-14T02:00:00.000ZWegovy and Mounjaro for weight loss not fundedhttps://www.pharmaradar360.com/article/be733b1bc134e0a3Pharma Surgeen2026-05-14T01:07:03.000ZNew psychedelic-like drugs could treat depression without making you triphttps://www.pharmaradar360.com/article/f282505dc65707eaPharma Surgeen2026-05-14T01:00:37.000ZUFRJ inaugura Centro de Livros da China na Faculdade de Letrashttps://www.pharmaradar360.com/article/30fa07b1e018c909Pharma Surgeen2026-05-14T00:00:00.000ZU.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapyhttps://www.pharmaradar360.com/article/82be4303a0e72c4bPharma Surgeen2026-05-14T00:00:00.000ZIntegrated single-cell and spatial transcriptomic profiling in ALS uncovers peripheral-to-central immune infiltration and reprogramminghttps://www.pharmaradar360.com/article/75c682b07ff438a3Pharma Surgeen2026-05-14T00:00:00.000ZSynchronous climbing fiber activity enables instructive signaling for cerebellar learning through modulation of disinhibitory circuitshttps://www.pharmaradar360.com/article/74e217b3f20f6197Pharma Surgeen2026-05-14T00:00:00.000ZAbatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trialhttps://www.pharmaradar360.com/article/968de70749b11faaPharma Surgeen2026-05-14T00:00:00.000ZPerformance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathyhttps://www.pharmaradar360.com/article/0a6a64b3ad1f4eebPharma Surgeen2026-05-14T00:00:00.000ZAdvancing conversational diagnostic AI with multimodal reasoninghttps://www.pharmaradar360.com/article/fc7411df76096d8cPharma Surgeen2026-05-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/37feff17dbd95f24Pharma Surgeen2026-05-14T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/428b30d7736dff33Pharma Surgeen2026-05-14T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/f29f63376a7ce163Pharma Surgeen2026-05-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/fa643f9f4135078bPharma Surgeen2026-05-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/7aab0ac0c139a5a8Pharma Surgeen2026-05-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/36785f37dfcd4a85Pharma Surgeen2026-05-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/20d8c191ab37642ePharma Surgeen2026-05-14T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/6270ec8ed96e3c5fPharma Surgeen2026-05-14T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/febb0e8ac6f26da3Pharma Surgeen2026-05-14T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/26e7a8d979b7eff0Pharma Surgeen2026-05-14T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/66b68dbab3305eb4Pharma Surgeen2026-05-14T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/cc484c65357b6968Pharma Surgeen2026-05-14T00:00:00.000Z6203https://www.pharmaradar360.com/article/b7e57133489b3fb7Pharma Surgeen2026-05-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/f84ca61d613e6c34Pharma Surgeen2026-05-14T00:00:00.000ZGH Research Reports First Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/80c783ee99a18e34Pharma Surgeen2026-05-13T23:38:09.000ZState health authorities investigating radiology group's handling of fatal MRI incidenthttps://www.pharmaradar360.com/article/95128c0201becf26Pharma Surgeen2026-05-13T23:18:47.000ZShoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlookhttps://www.pharmaradar360.com/article/e5f15fd4491de35ePharma Surgeen2026-05-13T22:58:32.000ZSimple measurement from routine X-rays accurately predicts post-op lung cancer outcomeshttps://www.pharmaradar360.com/article/506264ddc0fcfe6ePharma Surgeen2026-05-13T22:20:00.000ZSmith Entertainment Group and Intermountain Health Announce Groundbreaking Partnership and Creation of World-Class Sports Performance Center Co-located with Utah Jazz and Utah Mammoth Practice Facilitieshttps://www.pharmaradar360.com/article/ee4a4239ef082e4bPharma Surgeen2026-05-13T21:57:41.000ZVisualizing Receptor Transport Within Neurons via Transcytosishttps://www.pharmaradar360.com/article/0523acfe7df18242Pharma Surgeen2026-05-13T21:52:24.000ZChallenging negative stereotypes and embracing strengths associated with aginghttps://www.pharmaradar360.com/article/0d8664adf972f5abPharma Surgeen2026-05-13T21:19:03.000ZCytokine-Driven Divergence Between Allogeneic CAR-T Platformshttps://www.pharmaradar360.com/article/432475f9ef3c966dPharma Surgeen2026-05-13T21:13:10.000ZFinger Lakes Community Rallies Around New Opportunities at 2026 Tour de Cure Diabetes Fundraiserhttps://www.pharmaradar360.com/article/ce7339b7dbd71c0cPharma Surgeen2026-05-13T21:00:00.000ZAptose Reports First Quarter 2026 Resultshttps://www.pharmaradar360.com/article/323365cd69861adbPharma Surgeen2026-05-13T20:55:32.000ZPrincipales Logros Consejo Directivo y JVPS período 2024-2026https://www.pharmaradar360.com/article/94ada742e62ec3a1Pharma Surgeen2026-05-13T20:34:52.000ZBMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaborationhttps://www.pharmaradar360.com/article/6132b23d813b46fcPharma Surgeen2026-05-13T20:17:48.000ZBecker’s Highlights Improved Workplace Safety at Scrippshttps://www.pharmaradar360.com/article/94d362aa299ae23dPharma Surgeen2026-05-13T20:05:00.000ZTalphera Announces First Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/7784751b02f266cePharma Surgeen2026-05-13T20:05:00.000ZVivani Medical Reports First Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/b11d3d299fbec3c2Pharma Surgeen2026-05-13T20:02:00.000ZAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Updatehttps://www.pharmaradar360.com/article/8ad00941e67df021Pharma Surgeen2026-05-13T20:00:19.000ZASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Endshttps://www.pharmaradar360.com/article/401e57050b49f4f8Pharma Surgeen2026-05-13T19:59:00.000ZHelmsley Charitable Trust destina $20 millones para que Intermountain Health expanda los servicios de salud conductual pediátrica en Nevadahttps://www.pharmaradar360.com/article/6cf01ba81109d1acPharma Surgeen2026-05-13T19:58:09.000ZThe condition PCOS has a new name. Here’s what the change means for patientshttps://www.pharmaradar360.com/article/7bff82123258f5dbPharma Surgeen2026-05-13T19:57:10.000ZWhat a Student-Centered University Really Looks Likehttps://www.pharmaradar360.com/article/e0e39fa6774164a6Pharma Surgeen2026-05-13T19:55:59.000ZMichele Tafoya has the support of the national GOP, but winning over state activists is a challengehttps://www.pharmaradar360.com/article/c950bac32a73b296Pharma Surgeen2026-05-13T19:52:38.000ZSynthesizing a Natural Sunscreen and Antioxidant in E. colihttps://www.pharmaradar360.com/article/372f105dceb91e11Pharma Surgeen2026-05-13T19:44:58.000ZMaster Protocols in Oncology: A Biostatistics Execution Perspectivehttps://www.pharmaradar360.com/article/d8fd4553d9ab3f4aPharma Surgeen2026-05-13T19:44:58.000ZMaster Protocols in Oncology: A Biostatistics Execution Perspectivehttps://www.pharmaradar360.com/article/86aa97dfc433ee28Pharma Surgeen2026-05-13T19:42:48.000ZHelmsley Charitable Trust Commits $20 Million to Intermountain Health to Expand Pediatric Behavioral Health Services in Nevadahttps://www.pharmaradar360.com/article/14c6cb8aac7136e3Pharma Surgeen2026-05-13T19:22:00.000ZSalesforce, Echo Health Ventures back Optura's $17.5M series A to track AI performancehttps://www.pharmaradar360.com/article/ba76526b1f5adeb8Pharma Surgeen2026-05-13T18:50:53.000ZAfter an apparent cure, a gene editing company struggles to repeat the magichttps://www.pharmaradar360.com/article/971e0e5b456e1ed5Pharma Surgeen2026-05-13T18:45:21.000ZApexGO: AI-Driven Approach to Faster Antibiotic Discoveryhttps://www.pharmaradar360.com/article/cd3a5ccb3ed6536ePharma Surgeen2026-05-13T18:36:06.000ZTakeda to target 4,500 jobs as incoming CEO continues restructuringhttps://www.pharmaradar360.com/article/b67bce772e513971Pharma Surgeen2026-05-13T18:27:36.000ZCrossing Paths: How the National MPS Society Reaches Families Where They Arehttps://www.pharmaradar360.com/article/eb53bc4eb3bc2e3cPharma Surgeen2026-05-13T18:26:42.000ZPharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanuhttps://www.pharmaradar360.com/article/72f58385c70429dfPharma Surgeen2026-05-13T18:24:07.000ZANMAT impulsa la cooperación regulatoria regional y la actualización normativa dentro del Mercosurhttps://www.pharmaradar360.com/article/659173d549c60366Pharma Surgeen2026-05-13T18:00:00.000ZThe Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entryhttps://www.pharmaradar360.com/article/6d1760f3e973f95ePharma Surgeen2026-05-13T17:46:51.000ZValneva to cut up to 15% of jobs as reduced travel hits vaccine demandhttps://www.pharmaradar360.com/article/953b0e37619fc7baPharma Surgeen2026-05-13T17:25:00.000ZCMS to withhold $1.3B in Medicaid funds from California, puts state officials on notice about fraudhttps://www.pharmaradar360.com/article/9f28cd44e7407c25Pharma Surgeen2026-05-13T17:00:07.000ZWhy AI Alone Isn’t Enough for Oligonucleotide Discoveryhttps://www.pharmaradar360.com/article/03915122c22e889fPharma Surgeen2026-05-13T16:39:44.000ZCellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancerhttps://www.pharmaradar360.com/article/0ce5f53862a7705cPharma Surgeen2026-05-13T16:34:18.000ZThe American Diabetes Association Recognized for Workplace Wellnesshttps://www.pharmaradar360.com/article/d133fa6d504a88eePharma Surgeen2026-05-13T16:32:56.000ZBuilding Successful Viral Vector Production Processeshttps://www.pharmaradar360.com/article/9b95dc26bc17ef9ePharma Surgeen2026-05-13T16:23:29.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/1258741a164ad5a7Pharma Surgeen2026-05-13T16:22:00.000ZBeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphomahttps://www.pharmaradar360.com/article/cc9eaef8c09515a0Pharma Surgeen2026-05-13T16:04:06.000Z2026 elections in Scotland and Wales: a turning point for cancer?https://www.pharmaradar360.com/article/7fe4df189d4005f6Pharma Surgeen2026-05-13T16:01:21.000ZVoxCell BioInnovation & adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platformhttps://www.pharmaradar360.com/article/00c43c9b9bd5bc2bPharma Surgeen2026-05-13T16:00:52.000ZAdopting Creative Chemistry to Optimize Bioprocessing Workflowhttps://www.pharmaradar360.com/article/897dabf6079f9d34Pharma Surgeen2026-05-13T16:00:44.000ZYeast We Can: Cutting Costs by Optimizing Cell-Free Expression Systemshttps://www.pharmaradar360.com/article/b14f172ba7a72987Pharma Surgeen2026-05-13T16:00:29.000ZOperator Protection as Core Design Principle for ADC Bioprocessinghttps://www.pharmaradar360.com/article/fa048afebf1be3ccPharma Surgeen2026-05-13T16:00:00.000ZLife sciences ‘sweet’ opportunity in US-China talkshttps://www.pharmaradar360.com/article/55b5194f15523c28Pharma Surgeen2026-05-13T15:54:00.000ZNew payer-backed ad campaign pushes for No Surprises Act IDR reformhttps://www.pharmaradar360.com/article/591dc05fe2a22e70Pharma Surgeen2026-05-13T15:50:57.000ZScripps Cancer Center Expert Offers Tips to Keep Skin Safehttps://www.pharmaradar360.com/article/ce4657b62c4785daPharma Surgeen2026-05-13T15:36:52.000ZAbeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3https://www.pharmaradar360.com/article/c7f421965090e2b3Pharma Surgeen2026-05-13T15:28:36.000ZVetter Starts Construction of a New Production Site in Germanyhttps://www.pharmaradar360.com/article/bf21efe131b7ae75Pharma Surgeen2026-05-13T14:59:53.000ZLa UNLP realizó una nueva entrega de bicicletas a sus estudianteshttps://www.pharmaradar360.com/article/3a47b61017920671Pharma Surgeen2026-05-13T14:58:08.000ZMaintain Patient Trust: How to Use AI in Lay Summary Developmenthttps://www.pharmaradar360.com/article/8a2577d7ea764e48Pharma Surgeen2026-05-13T14:52:00.000ZDocs more burned out, skeptical of AI than nurses, survey report findshttps://www.pharmaradar360.com/article/829324d503411656Pharma Surgeen2026-05-13T14:46:37.000ZPost-Hoc: Why FDA Commissioner Marty Makary was oustedhttps://www.pharmaradar360.com/article/47a218bc4db3b87bPharma Surgeen2026-05-13T14:42:50.000ZLa AEMPS publica las instrucciones para la utilización de códigos QR en el prospecto y/o etiquetado de los medicamentoshttps://www.pharmaradar360.com/article/fdefdbf1fbe6e09ePharma Surgeen2026-05-13T14:30:46.000ZEconomía circular: en alianza con productores locales, nace el tomate deshidratado de la UNLPhttps://www.pharmaradar360.com/article/28665a7cf2a75211Pharma Surgeen2026-05-13T14:30:10.000ZLa UNLP en un relevamiento inédito en barrios populares de La Plata, Berisso y Ensenadahttps://www.pharmaradar360.com/article/ede14e51d6abc9a1Pharma Surgeen2026-05-13T14:29:59.000ZThis daily habit could lower dementia risk by 35%, scientists sayhttps://www.pharmaradar360.com/article/e20ce4a9642da36cPharma Surgeen2026-05-13T14:25:58.000ZMedicaid Mental Health and Substance Use: Expansion Trends and the Fiscal Pressure Aheadhttps://www.pharmaradar360.com/article/f4219a785d4c8b28Pharma Surgeen2026-05-13T14:25:04.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/d4cea4995717851cPharma Surgeen2026-05-13T14:22:48.000Z‘I want to help patients'https://www.pharmaradar360.com/article/25e9033a71cee4a2Pharma Surgeen2026-05-13T14:21:53.000ZTree communities influence food webs in European forest floorshttps://www.pharmaradar360.com/article/c6b45cd2dddbe22dPharma Surgeen2026-05-13T14:10:52.000ZNew findings link common pesticide to early-onset colorectal cancerhttps://www.pharmaradar360.com/article/c8cb09ea796f7ca6Pharma Surgeen2026-05-13T14:00:00.000ZBeing an Expert Is About More Than Just Knowing the Answershttps://www.pharmaradar360.com/article/bfd21d73a0a36177Pharma Surgeen2026-05-13T14:00:00.000ZAcoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapyhttps://www.pharmaradar360.com/article/017d985d2a45cf2cPharma Surgeen2026-05-13T14:00:00.000ZPremotor cortex hemodynamic responses primarily reflect perceptual rather than specific motor aspects of decision makinghttps://www.pharmaradar360.com/article/73f7e93586d69714Pharma Surgeen2026-05-13T13:59:17.000ZUC Irvine researchers invent a wearable, bioelectronic sweat sensor for long-term health monitoringhttps://www.pharmaradar360.com/article/d08aceb03250818fPharma Surgeen2026-05-13T13:55:01.000ZBiventricular repair linked to better outcomes in superior-inferior ventricles treatmenthttps://www.pharmaradar360.com/article/9fa2b408cfc48b21Pharma Surgeen2026-05-13T13:53:00.000ZAs Trump arrives in China, Big Pharma CEOs are notably absenthttps://www.pharmaradar360.com/article/b2ce00edff7095b0Pharma Surgeen2026-05-13T13:52:51.000ZECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body compositionhttps://www.pharmaradar360.com/article/aa8957fa1936e674Pharma Surgeen2026-05-13T13:47:30.000ZEli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectableshttps://www.pharmaradar360.com/article/2373546ebee97637Pharma Surgeen2026-05-13T13:43:26.000ZOrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development & Manufacturing Organizationhttps://www.pharmaradar360.com/article/320a2610a8796e5bPharma Surgeen2026-05-13T13:39:15.000ZReformulation, Resilience, and the Race for Relevance in 2026https://www.pharmaradar360.com/article/7880adffa4de6ae5Pharma Surgeen2026-05-13T13:38:22.000ZNorstellaLinQ: Identify obesity treatment opportunity before the market doeshttps://www.pharmaradar360.com/article/b0dda03f9a96593ePharma Surgeen2026-05-13T13:35:00.000ZOrganspende – eine Frage des Alters?https://www.pharmaradar360.com/article/aa755a46ed4e80caPharma Surgeen2026-05-13T13:30:48.000ZBehind Galapagos’ transformation into Lakefront Biotherapeuticshttps://www.pharmaradar360.com/article/6a56721f2671ca5aPharma Surgeen2026-05-13T13:30:04.000ZSCI-TIF community gathers for 4th Annual Networking Dinnerhttps://www.pharmaradar360.com/article/2a56fda4f1e8e2f9Pharma Surgeen2026-05-13T13:29:51.000ZGirls Play Global thanks to this Tar Heelhttps://www.pharmaradar360.com/article/a2a840ccbb6a61cePharma Surgeen2026-05-13T13:21:12.000ZRigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanuhttps://www.pharmaradar360.com/article/cf4f9abfa50af692Pharma Surgeen2026-05-13T13:18:00.000ZIcon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilitieshttps://www.pharmaradar360.com/article/0399b812be38518bPharma Surgeen2026-05-13T13:14:59.000ZInnovative heart failure treatment proves transformative for patientshttps://www.pharmaradar360.com/article/bb963c23301576a6Pharma Surgeen2026-05-13T13:07:00.000ZCMS pauses hospice, home health Medicare enrollments in fraud crackdownhttps://www.pharmaradar360.com/article/e98410d686e7ebc7Pharma Surgeen2026-05-13T13:00:00.000ZWhat investors now expect from AI biotech companieshttps://www.pharmaradar360.com/article/44ffa98e6c300711Pharma Surgeen2026-05-13T12:59:37.000ZDiretores e decanos debatem protocolo institucional para situações de violência urbanahttps://www.pharmaradar360.com/article/bbb89beddd57c906Pharma Surgeen2026-05-13T12:57:05.000ZTerumo Blood & Cell Technologies & Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturinghttps://www.pharmaradar360.com/article/46982412ddb77920Pharma Surgeen2026-05-13T12:46:14.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/ef845f38b36f9b6bPharma Surgeen2026-05-13T12:45:11.000ZThe Pharma Days 2026https://www.pharmaradar360.com/article/a9e28e18bed6d05bPharma Surgeen2026-05-13T12:44:48.000ZZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitorhttps://www.pharmaradar360.com/article/d61a0ccd9b85693bPharma Surgeen2026-05-13T12:43:11.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/b04c626263a2303bPharma Surgeen2026-05-13T12:38:36.000ZMedical devices: conformity assessment and the UKCA markhttps://www.pharmaradar360.com/article/f288ba6278c0ac03Pharma Surgeen2026-05-13T12:30:59.000ZHarrogate and District launches phase two of Nervecentre EPRhttps://www.pharmaradar360.com/article/1e4baa8f920190b5Pharma Surgeen2026-05-13T12:25:00.000ZPharmaceutical Traceability & Supply Chain Monitoringhttps://www.pharmaradar360.com/article/bfd39b494e82a242Pharma Surgeen2026-05-13T12:24:51.000ZSCiLL to become independent academic unithttps://www.pharmaradar360.com/article/15b802e0d4093001Pharma Surgeen2026-05-13T12:17:06.000ZStrengthening the knowledge base for EU climate policyhttps://www.pharmaradar360.com/article/5c5ce154c5c78bdePharma Surgeen2026-05-13T12:06:11.000ZPresentation of #DHH26 Hackathon projects on 29rd May 2026https://www.pharmaradar360.com/article/a423f19675f53a91Pharma Surgeen2026-05-13T12:00:56.000ZTessera reveals strongest data yet for in vivo sickle cell therapyhttps://www.pharmaradar360.com/article/eab3691dd6cddaf3Pharma Surgeen2026-05-13T12:00:00.000ZICON expands US early phase research capabilitieshttps://www.pharmaradar360.com/article/9e00b8ee1c3e2d47Pharma Surgeen2026-05-13T12:00:00.000ZCharles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutionshttps://www.pharmaradar360.com/article/5db6def23c5c31a6Pharma Surgeen2026-05-13T11:56:03.000ZJellinek Dialogues: Power Conflicts in Researchhttps://www.pharmaradar360.com/article/9e7deb126e28d07aPharma Surgeen2026-05-13T11:54:28.000ZAcreditados | Acreditación de Proyectos I+D y PPID 2026https://www.pharmaradar360.com/article/bdb669df1802d9f4Pharma Surgeen2026-05-13T11:30:00.000ZAbeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Updatehttps://www.pharmaradar360.com/article/778788e8e0b81ce3Pharma Surgeen2026-05-13T11:24:00.000ZNYU Langone Health says it received grand jury subpoena over gender-affirming carehttps://www.pharmaradar360.com/article/8718035ae9ee1941Pharma Surgeen2026-05-13T11:22:31.000ZAlexander von Humboldt professorship for Simon Elsässer – “You can think of it as a kind of cellular memory”https://www.pharmaradar360.com/article/8b68224d06048519Pharma Surgeen2026-05-13T11:22:00.000ZMerck KGaA looks to M&A to bolster its 'rather slim' pipelinehttps://www.pharmaradar360.com/article/1835b415a4acd9b0Pharma Surgeen2026-05-13T11:21:00.000ZTakeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drivehttps://www.pharmaradar360.com/article/040b30097badf46dPharma Surgeen2026-05-13T11:18:04.000ZResearch Sheds Light on Modern Myth Retellingshttps://www.pharmaradar360.com/article/16bc52f00320aa49Pharma Surgeen2026-05-13T11:14:27.000Z6 Fragen an Prof. Carolin Lerchenmüller zur Frauen Herzsprechstundehttps://www.pharmaradar360.com/article/25f5fa899e4cd670Pharma Surgeen2026-05-13T11:13:00.000ZBeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'https://www.pharmaradar360.com/article/38f98ad96c358d5fPharma Surgeen2026-05-13T11:11:00.000ZHealth systems are exploring AI-powered cardiac risk screening. New CMS reimbursement could unlock a business case for ithttps://www.pharmaradar360.com/article/085dd95496093feaPharma Surgeen2026-05-13T11:05:00.000ZMost mental health practitioners satisfied with work, financially stable, SimplePractice findshttps://www.pharmaradar360.com/article/69ed610c08fb71ebPharma Surgeen2026-05-13T11:01:36.000ZMerck KGaA's clients are stockpiling due to Iran war, supporting guidance boosthttps://www.pharmaradar360.com/article/dd746bd14476df37Pharma Surgeen2026-05-13T11:01:29.000ZΑνάκληση των κωδικών του συνημμένου πίνακα, του Ιατροτεχνολογικού προϊόντος SplashWire Hydrophilic Steerable Guide Wire, (Υδρόφιλο κατευθυνόμενο σύρμα οδηγού SplashWire)https://www.pharmaradar360.com/article/94b0d8f6fc4b720bPharma Surgeen2026-05-13T11:00:00.000ZGhost of long-extinct ancestor lives on in people todayhttps://www.pharmaradar360.com/article/9ed772270f11f632Pharma Surgeen2026-05-13T10:54:48.000ZMarcha federal por la Universidad Públicahttps://www.pharmaradar360.com/article/05fc4a69fddc98c7Pharma Surgeen2026-05-13T10:51:53.000ZInternationaler Tag der Pflegenden 2026 am UKHDhttps://www.pharmaradar360.com/article/b9b1cd7efdb8eb0fPharma Surgeen2026-05-13T10:51:00.000ZNovo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifieshttps://www.pharmaradar360.com/article/b3824692d5b1a202Pharma Surgeen2026-05-13T10:47:44.000ZAcne in estate: come averne curahttps://www.pharmaradar360.com/article/b8eee50705b58146Pharma Surgeen2026-05-13T10:43:35.000ZMedicines Pipeline datahttps://www.pharmaradar360.com/article/ffdd2e898c9c05b2Pharma Surgeen2026-05-13T10:38:14.000ZFIMM Genomics Eventshttps://www.pharmaradar360.com/article/48fb9e8833757d92Pharma Surgeen2026-05-13T10:37:33.000ZNovo Nordisk’s high-dose Wegovy touts near 28% weight loss in early respondershttps://www.pharmaradar360.com/article/8f32da17e7b07f79Pharma Surgeen2026-05-13T10:35:00.000ZFluffy ice could imperil spacecraft landings on ocean moonshttps://www.pharmaradar360.com/article/445238a9f892e27dPharma Surgeen2026-05-13T10:35:00.000ZHaleon tackles sports injuries with latest soccer playhttps://www.pharmaradar360.com/article/4166695ccb03232ePharma Surgeen2026-05-13T10:33:20.000ZEU advances plans to reduce reliance on drug importshttps://www.pharmaradar360.com/article/ea1fd28128e88b6cPharma Surgeen2026-05-13T10:29:31.000ZSimultaneous Tricuspid Valve Replacement and Left Bundle Branch Area Pacing With Surgical Lead Refixationhttps://www.pharmaradar360.com/article/17fab6530971dba2Pharma Surgeen2026-05-13T10:23:33.000ZEnterprise’s Phase II trial of ETD001 meets primary endpoint in pwCFhttps://www.pharmaradar360.com/article/7e07a3ae743169e2Pharma Surgeen2026-05-13T10:21:26.000ZCosa sono e a cosa servono le paratiroidi?https://www.pharmaradar360.com/article/bcce517ba0243581Pharma Surgeen2026-05-13T10:20:07.000ZLeft Atrial Appendage Thrombus/Sludge and Flow Velocity in Patients With Atrial Fibrillation and Low CHA2DS2‐VASc Scoreshttps://www.pharmaradar360.com/article/af3f2b169a174550Pharma Surgeen2026-05-13T10:17:21.000ZZero Fluoroscopy Catheter Ablation of Accessory Pathways and AV Nodal Re‐Entry Tachycardia: A Single Institution Studyhttps://www.pharmaradar360.com/article/e773e86254f89527Pharma Surgeen2026-05-13T10:14:57.000ZUAE approves AstraZeneca’s Baxfendy for hypertensionhttps://www.pharmaradar360.com/article/36969b1503ec5e71Pharma Surgeen2026-05-13T10:09:38.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/1b3628b5023e8bdcPharma Surgeen2026-05-13T10:02:47.000ZZymeworks Announces Participation in Upcoming Investor Conferenceshttps://www.pharmaradar360.com/article/f264068852a10666Pharma Surgeen2026-05-13T10:00:55.000ZLa AEMPS informa de un riesgo en los paquetes de baterías Zinc-Aire M de los procesadores de sonido de Advanced Bionicshttps://www.pharmaradar360.com/article/a507e68d883ef659Pharma Surgeen2026-05-13T10:00:32.000ZHealth innovation minister Zubir Ahmed resignshttps://www.pharmaradar360.com/article/28e69735c05df1a2Pharma Surgeen2026-05-13T10:00:00.000ZThe Risks of Conflating Science with Politicshttps://www.pharmaradar360.com/article/4b6aa3b1624c5e3fPharma Surgeen2026-05-13T10:00:00.000ZDeveloping New Therapies Across Multiple Regulatory Landscapeshttps://www.pharmaradar360.com/article/b8f4fcb251bcd285Pharma Surgeen2026-05-13T09:44:16.000ZNHSGGC highlights blueprint to improve access to local healthcare serviceshttps://www.pharmaradar360.com/article/8640740a31c51048Pharma Surgeen2026-05-13T09:36:00.000ZWith $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’https://www.pharmaradar360.com/article/07d3a53ab9a7dde2Pharma Surgeen2026-05-13T09:35:48.000ZNext generation of Nightingales honoured with unique professional awardhttps://www.pharmaradar360.com/article/b7d723a2a5711c06Pharma Surgeen2026-05-13T09:25:08.000ZKahimmune Therapeutics signe un accord de collaboration scientifique avec Gustave Roussyhttps://www.pharmaradar360.com/article/2702e754e0cd8703Pharma Surgeen2026-05-13T09:16:00.000ZFosun pays $60M for option on AriBio’s phase 3 Alzheimer’s assethttps://www.pharmaradar360.com/article/dce97d04b90196d2Pharma Surgeen2026-05-13T09:00:03.000ZEditing tRNA Genes to Broaden Nonsense Therapeuticshttps://www.pharmaradar360.com/article/2ff5d8db13b6ba1fPharma Surgeen2026-05-13T09:00:03.000ZInflammatory Myopathieshttps://www.pharmaradar360.com/article/4b035f4f19b3bc37Pharma Surgeen2026-05-13T09:00:03.000ZHow Did Race Get Into Lung Testing?https://www.pharmaradar360.com/article/4bb66b150ec46e33Pharma Surgeen2026-05-13T09:00:03.000ZTelitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trialhttps://www.pharmaradar360.com/article/e89642d0ca873931Pharma Surgeen2026-05-13T09:00:03.000ZEndovascular Treatment of Medium-Vessel-Occlusion Strokeshttps://www.pharmaradar360.com/article/86ce4a7a8ecdebbdPharma Surgeen2026-05-13T09:00:03.000ZEnsitrelvir for Covid-19 Postexposure Prophylaxis in Household Contactshttps://www.pharmaradar360.com/article/1cdb743854c152eePharma Surgeen2026-05-13T09:00:03.000ZCentral Retinal-Vein Occlusionhttps://www.pharmaradar360.com/article/e235f59d683b6157Pharma Surgeen2026-05-13T09:00:03.000ZInhalation Injury from House Fire Smokehttps://www.pharmaradar360.com/article/31139fc6d67869d1Pharma Surgeen2026-05-13T09:00:03.000ZA Phase 3 Trial of Brepocitinib in Dermatomyositishttps://www.pharmaradar360.com/article/1dbbb85bc2b9f5faPharma Surgeen2026-05-13T09:00:03.000ZEndovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Populationhttps://www.pharmaradar360.com/article/785324a324601797Pharma Surgeen2026-05-13T09:00:03.000ZCase 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemiahttps://www.pharmaradar360.com/article/da83666f86af67daPharma Surgeen2026-05-13T09:00:03.000ZCabotegravir plus Rilpivirine for Persons with HIV and Adherence Challengeshttps://www.pharmaradar360.com/article/543ff4e4ba8d057aPharma Surgeen2026-05-13T09:00:03.000ZTherapy for Atrial Fibrillation in Patients with Drug-Eluting Stentshttps://www.pharmaradar360.com/article/da3ab8c9eb99ed5aPharma Surgeen2026-05-13T09:00:03.000ZTargeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathyhttps://www.pharmaradar360.com/article/ffe7cb19764eb9b3Pharma Surgeen2026-05-13T09:00:03.000ZThe Inherited Basis of Coronary Artery Diseasehttps://www.pharmaradar360.com/article/db7bec3bdd89d793Pharma Surgeen2026-05-13T09:00:03.000ZCurrent Causes of Death among Children and Adolescents in the United Stateshttps://www.pharmaradar360.com/article/1c0f9e5a77e281f3Pharma Surgeen2026-05-13T09:00:03.000ZDulaglutide-Associated Choroidal Lymphoid Hyperplasiahttps://www.pharmaradar360.com/article/ea938a6faca95d7cPharma Surgeen2026-05-13T09:00:00.000ZTalent, humour and science communication shine at the first “Science on Stage: Research Takes the Stage” monologue competitionhttps://www.pharmaradar360.com/article/99cbf37e8d3a7b4dPharma Surgeen2026-05-13T09:00:00.000ZPerimenopause may offer a “window of opportunity” for heart disease prevention in womenhttps://www.pharmaradar360.com/article/9cdddbeae09f9af5Pharma Surgeen2026-05-13T08:59:51.000ZLa AEMPS informa de la retirada de dos lotes del medicamento veterinario Febrinol SP 650mg/g, polvo para administración en agua de bebida para cerdos de engorde y pollos de engordehttps://www.pharmaradar360.com/article/147e435381dd79f2Pharma Surgeen2026-05-13T08:56:53.000ZFEBRINOL S.P. 650 MG/G POLVO PARA ADMINISTRACION EN AGUA DE BEBIDA PARA CERDOS DE ENGORDE Y POLLOS DE ENGORDE (Nº 1647 ESP)https://www.pharmaradar360.com/article/794135d47a351a5ePharma Surgeen2026-05-13T08:52:09.000Z«Ich analysiere leidenschaftlich gerne Daten.»https://www.pharmaradar360.com/article/70ca39f48c384b7dPharma Surgeen2026-05-13T08:40:36.000ZHarnessing AI for more efficient clinical trialshttps://www.pharmaradar360.com/article/e2a62462a8703c45Pharma Surgeen2026-05-13T08:35:29.000ZPlastische Chirurgie zwischen Social-Media-Filtern und Realitäthttps://www.pharmaradar360.com/article/2d45eaf03aaf7840Pharma Surgeen2026-05-13T08:30:30.000ZStudents and researchers from Erasmus University joined hundreds of women advocating for gender justicehttps://www.pharmaradar360.com/article/a09f21c45bbcc4b4Pharma Surgeen2026-05-13T08:22:00.000ZHumacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implanthttps://www.pharmaradar360.com/article/4db0401c7761f6e3Pharma Surgeen2026-05-13T08:21:00.000Z#RASSEGNASTAMPA. L'algoritmo in corsia: Matteo Stocco ai microfoni di Radio Lombardia per parlare degli utilizzi dell'IA in Policlinico di Milanohttps://www.pharmaradar360.com/article/142b94c35772c21ePharma Surgeen2026-05-13T08:18:00.000ZMedtronic to shutter Santa Rosa plant as it restructures cardiovascular unithttps://www.pharmaradar360.com/article/234b526aaf02f846Pharma Surgeen2026-05-13T08:16:00.000ZTwo researchers from the Nuffield Department of Clinical Neurosciences (NDCN) join global network to unravel the complexity of Parkinson’s diseasehttps://www.pharmaradar360.com/article/bbc7155179299079Pharma Surgeen2026-05-13T08:12:03.000ZAI tools life sciences companieshttps://www.pharmaradar360.com/article/1332ba8f994cf842Pharma Surgeen2026-05-13T08:11:43.000ZAlkermes reports encouraging data from Phase III study of Lumryzhttps://www.pharmaradar360.com/article/68591dddf429e4e4Pharma Surgeen2026-05-13T08:07:33.000ZIsomorphic Labs receives $2.1bn for AI drug developmenthttps://www.pharmaradar360.com/article/3f5b41898f7eb434Pharma Surgeen2026-05-13T08:03:00.000ZTIL therapies: the impact on cancer researchhttps://www.pharmaradar360.com/article/dfc5d6968887428aPharma Surgeen2026-05-13T08:01:16.000ZStudy aims to unlock causes of ME/CFS and Long Covidhttps://www.pharmaradar360.com/article/4a7af8c29846d6f2Pharma Surgeen2026-05-13T07:54:47.000ZAmerican Society for Nutrition Foundation and Novo Nordisk Foundation announce 2026 awardees advancing nutrition and obesity sciencehttps://www.pharmaradar360.com/article/de94ad7aa184b315Pharma Surgeen2026-05-13T07:47:29.000ZPatients are discussing whole-body MRIs on Reddit, presenting opportunity for radiologistshttps://www.pharmaradar360.com/article/0e4f6e6bb8edaf85Pharma Surgeen2026-05-13T07:41:03.000ZLumexa acquires imaging center as part of new joint venture with UPMChttps://www.pharmaradar360.com/article/9be8725303826f54Pharma Surgeen2026-05-13T07:35:11.000ZNovel urine test reduces need for MR imaging, prostate biopsieshttps://www.pharmaradar360.com/article/b0b303f8e96a721aPharma Surgeen2026-05-13T07:16:01.000ZAnti-Gender Trouble Workshop 3/26 with Ulrika Dahl in University of Uppsalahttps://www.pharmaradar360.com/article/5883b72f06b78574Pharma Surgeen2026-05-13T07:00:00.000ZAnatomy lab named in honor of Saxenas’ journey in medicinehttps://www.pharmaradar360.com/article/9216809527a93658Pharma Surgeen2026-05-13T07:00:00.000ZRNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type Ihttps://www.pharmaradar360.com/article/a4d5659f5e8b9992Pharma Surgeen2026-05-13T07:00:00.000ZSensory nerves protect against preclinical tendinopathic changes through FGF1 signalinghttps://www.pharmaradar360.com/article/57729ec30e4b2b06Pharma Surgeen2026-05-13T07:00:00.000ZA platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical carehttps://www.pharmaradar360.com/article/1aa8e298d2398865Pharma Surgeen2026-05-13T07:00:00.000ZuPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell targethttps://www.pharmaradar360.com/article/da9986975c06624bPharma Surgeen2026-05-13T07:00:00.000ZPrime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS+ mouse modelhttps://www.pharmaradar360.com/article/7d6cba1be2415ad2Pharma Surgeen2026-05-13T07:00:00.000ZIn vivo adenine base editing ameliorates Dravet syndrome phenotypes in a mouse modelhttps://www.pharmaradar360.com/article/8cf2a20b9c99c08ePharma Surgeen2026-05-13T07:00:00.000ZNatural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblastshttps://www.pharmaradar360.com/article/8571552498cbb224Pharma Surgeen2026-05-13T07:00:00.000ZAdvancing emphysema care: UC Davis Health offers innovative lung treatmenthttps://www.pharmaradar360.com/article/343f81dd8415b872Pharma Surgeen2026-05-13T06:58:00.000ZScott Ehresman, MD, honored as 2026 Koefoot Award recipienthttps://www.pharmaradar360.com/article/918c7e65d6d0f4bePharma Surgeen2026-05-13T06:56:00.000ZCancer center hosts Midwest Data Partner’s Workshophttps://www.pharmaradar360.com/article/0469e16f9d6818dcPharma Surgeen2026-05-13T06:54:00.000ZGlobal engagement announces International Photo Contest winnershttps://www.pharmaradar360.com/article/434c1c39cdd02ca1Pharma Surgeen2026-05-13T06:52:00.000ZUNMC blood drive scheduled for May 18https://www.pharmaradar360.com/article/72dba2ffe3b76e78Pharma Surgeen2026-05-13T06:47:18.000ZVill du bidra till bättre vård? Bli en levande bok i VGRhttps://www.pharmaradar360.com/article/97aff442292540e4Pharma Surgeen2026-05-13T06:30:03.000ZRepairing EPR data errors could cost NHS at least £13.5m in 2026https://www.pharmaradar360.com/article/997907be5f439160Pharma Surgeen2026-05-13T06:30:00.000ZBoy’s brain tumor tied to gene therapyhttps://www.pharmaradar360.com/article/fbe7b8a39649216cPharma Surgeen2026-05-13T06:26:00.000ZValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccineshttps://www.pharmaradar360.com/article/42bcb58f7b78a5bcPharma Surgeen2026-05-13T06:26:00.000ZValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccineshttps://www.pharmaradar360.com/article/c10b1b23e88af6ffPharma Surgeen2026-05-13T06:23:31.000ZThe Nagoya Protocol: what is it and what scientists should know about compliancehttps://www.pharmaradar360.com/article/939329480d3c6ee5Pharma Surgeen2026-05-13T06:05:49.000ZNotice of Preliminary Results and Investor Presentationhttps://www.pharmaradar360.com/article/262427612cf95399Pharma Surgeen2026-05-13T06:04:22.000ZIssue of Equity and Total Voting Rightshttps://www.pharmaradar360.com/article/7ffb8593e7869476Pharma Surgeen2026-05-13T05:59:00.000ZBilancio di sostenibilità del Policlinico di Milano. La tua opinione per noi conta. Compila il questionario!